RxDoctor Payments Data

Iouri Sobol, MD

Internal Medicine · Brooklyn, NYNPI 1134124464

Payments from drug & device makers

$2,413in general payments, 2019–2025

Across 116 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$681
  • Amarin Pharma, Inc.$274
  • Lilly USA, LLC$266
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$180
  • Nestle Healthcare Nutrition Inc.$172
  • Pfizer$133
  • plus $707 from 12 others

What the payments were for

  • Food & beverage$2,402100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,413 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$268,901
Medicare patients
269
Services billed
3,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban408$273,857
JardianceEmpagliflozin311$211,308
JanuviaSitagliptin Phosphate163$91,935
LinzessLinaclotide162$84,850
MyrbetriqMirabegron175$82,478
OzempicSemaglutide86$79,853
Taltz SyringeIxekizumab12$77,537
MultaqDronedarone Hcl92$75,757
VascepaIcosapent Ethyl188$72,971
EntrestoSacubitril/Valsartan71$51,822
TrulicityDulaglutide50$50,335
ZenpepLipase/Protease/Amylase45$50,166
TradjentaLinagliptin100$49,725
JanumetSitagliptin Phos/Metformin Hcl77$49,437
CreonLipase/Protease/Amylase85$44,470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$133$273,857408 claims
Boehringer IngelheimJardiance, Tradjenta$69$261,033411 claims
MerckJanuvia, Janumet, Verquvo, Janumet Xr$681$205,782345 claims
AbbVieLinzess, Creon, Namzaric, Synthroid$101$177,520559 claims
Sanofi-aventis U.S. LLCMultaq$56$75,75792 claims
NovartisEntresto$42$51,82271 claims
Lilly USA, LLCTrulicity$266$50,33550 claims
Johnson & JohnsonXarelto, Invokana$33$33,22743 claims
AmgenProlia$121$28,94018 claims
AstraZenecaFarxiga$90$10,21314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →